Literature DB >> 20408945

Comorbidities associated with the increasing burden of hepatitis C infection.

Benjamin Basseri1, David Yamini, Grace Chee, Pharm D Pedram Enayati, Tram Tran, Fred Poordad.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is implicated in an increasing number of liver transplantations, hospitalizations and healthcare costs. AIMS: We present an updated assessment of comorbidities associated with HCV in comparison to the general US population.
METHODS: Cross-sectional retrospective review of data from 800 patients with HCV evaluated between January 1998 and November 2007. Patient data were prospectively collected using a standardized questionnaire completed at the first encounter and was compared with general US epidemiological data. Odds ratios and 95% confidence intervals (CI) are reported.
RESULTS: HCV conferred a 44% (CI 1.16-1.78) and 25% (CI 1.01-1.54) increased risk of diabetes (12.5 vs. 7.3-8.4%; P=0.001) and obesity (23.9 vs. 19.8-33.1%; P=0.041), respectively, compared with the US population. Human immunodeficiency virus (HIV) (5.3 vs. 0.3%; P<0.001) and end-stage renal disease (ESRD) (4.5 vs. 0.2%; P<0.001) were 16- and 13-fold more prevalent in HCV. Interestingly, HCV bestowed 90% decreased odds (CI 0.09-0.15) for hyperlipidaemia (12.3 vs. 53.2-56.1%; P<0.001). The HCV population had a higher prevalence of significant alcohol consumption (41.5 vs. 4.7%; P<0.001), current smoking (57.7 vs. 18.8-20.8%; P<0.001), drug use (46.8 vs. 14.6-15.6%; P<0.001), incarceration (6.6 vs. 2.7%; P<0.001) and tattoos (20.3 vs. 14%; P=0.011), as well as chronic fatigue (44.6 vs. 11.3-19%; P<0.001) and depression (29.3 vs. 5.0-10.3%; P<0.001).
CONCLUSION: HCV poses an increasing healthcare burden associated with increased prevalence of diabetes, obesity, HIV, ESRD, maladaptive lifestyle habits and poor quality of life. Practitioners should be cognizant of these trends in order to appropriately manage these comorbidities.

Entities:  

Mesh:

Year:  2010        PMID: 20408945     DOI: 10.1111/j.1478-3231.2010.02235.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  19 in total

1.  Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study.

Authors:  Sebastiano Leone; Patrizia Lorenzini; Alessandro Cozzi-Lepri; Giancarlo Orofino; Dario Bernacchia; Antonella Castagna; Marianna Menozzi; Giovanni Guaraldi; Giordano Madeddu; Antonio Di Biagio; Massimo Puoti; Andrea Gori; Antonella d'Arminio Monforte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-22       Impact factor: 3.267

2.  Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.

Authors:  Donna M Evon; Carol E Golin; Paul Stewart; Michael W Fried; Shani Alston; Bryce Reeve; Anna S Lok; Richard K Sterling; Joseph K Lim; Nancy Reau; Souvik Sarkar; David R Nelson; K R Reddy; Adrian M Di Bisceglie
Journal:  Contemp Clin Trials       Date:  2017-03-22       Impact factor: 2.226

3.  Prospective Longitudinal Substance Use Patterns in Patients Preparing for Hepatitis C Treatment.

Authors:  Carol S North; David E Pollio; Omar T Sims; Mamta K Jain; Barry A Hong
Journal:  J Dual Diagn       Date:  2018-01-18

4.  Major depression and generalized anxiety disorder among human T-lymphotropic virus types I- and II-infected former blood donors.

Authors:  Anne M Guiltinan; Zhanna Kaidarova; Dee Behan; Cheryl Marosi; Sheila Hutching; Mandi Kaiser; Elane Moore; Deborah Devita; Edward L Murphy
Journal:  Transfusion       Date:  2012-05-03       Impact factor: 3.157

5.  Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity.

Authors:  Barbara J Brennan; Zhi-Xin Xu; Joseph F Grippo
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

6.  Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.

Authors:  Julie C Lauffenburger; Christina L Mayer; Roy L Hawke; Kim L R Brouwer; Michael W Fried; Joel F Farley
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-10       Impact factor: 2.566

7.  Alcohol intake alters immune responses and promotes CNS viral persistence in mice.

Authors:  Jennifer M Loftis; Jonathan Taylor; Hans-Peter Raué; Mark K Slifka; Elaine Huang
Journal:  Behav Brain Res       Date:  2016-06-04       Impact factor: 3.332

8.  Initial implementation and evaluation of a Hepatitis C treatment clinical decision support system (CDSS): a nurse practitioner-driven quality improvement initiative.

Authors:  L Fathauer; J Meek
Journal:  Appl Clin Inform       Date:  2012-09-19       Impact factor: 2.342

9.  Cigarette Smoking Behaviors and Beliefs in Persons Living With Hepatitis C.

Authors:  Jonathan Shuter; Alain H Litwin; Mark S Sulkowski; Addi Feinstein; Avram Bursky-Tammam; Stephen Maslak; Andrea H Weinberger; Hannah Esan; Kate S Segal; Brianna Norton
Journal:  Nicotine Tob Res       Date:  2017-07-01       Impact factor: 4.244

10.  A Randomized Trial Comparing Brief Advice and Motivational Interviewing for Persons with HIV-HCV Co-infection Who Drink Alcohol.

Authors:  Michael D Stein; Debra S Herman; H Nina Kim; Abigail Howell; Audrey Lambert; Stephanie Madden; Ethan Moitra; Claire E Blevins; Bradley J Anderson; Lynn E Taylor; Megan M Pinkston
Journal:  AIDS Behav       Date:  2020-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.